Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.55 |
| ▸ | CNR2 | P34972 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.49 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.49 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2232371 | 1.00 | CNR1 (0.55) | CNR1CNR2ALDH1A1USP2PLA2G2C | |
| SCHEMBL2231650 | 1.00 | CNR1 (0.55) | CNR1CNR2ALDH1A1USP2PLA2G2C | |
| SCHEMBL2233827 | 1.00 | CNR1 (0.55) | CNR1CNR2ALDH1A1USP2PLA2G2C | |
| SCHEMBL707510 | 1.00 | CNR1 (0.55) | CNR1CNR2ALDH1A1USP2PLA2G2C | |
| SCHEMBL24207961 | 0.94 | CNR1 (0.45) | CNR1CNR2ALDH1A1USP2PLA2G2C | |
| SCHEMBL17577412 | 0.89 | LPAR1 (0.50) | CNR1CNR2ALDH1A1USP2PLA2G2C | |
| SCHEMBL10492075 | 0.88 | CNR1 (0.71) | CNR1CNR2ALDH1A1USP2LPAR1 | |
| SCHEMBL10492007 | 0.88 | CNR1 (0.71) | CNR1CNR2ALDH1A1USP2LPAR1 | |
| SCHEMBL16086106 | 0.88 | CNR1 (0.71) | CNR1CNR2ALDH1A1USP2LPAR1 | |
| SCHEMBL24208055 | 0.88 | CNR1 (0.71) | CNR1CNR2ALDH1A1USP2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206206-B2 | Oxidized lipid compounds and uses thereof | VASCULAR BIOGENICS LTD. (IL) | 2015-12-08 | — | — | US | disclosed |
| EP-2826370-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2826369-A2 | Oxidized lipid compounds and uses thereof | Vascular Biogenics Ltd. (IL) | 2015-01-21 | — | — | EP | disclosed |
| EP-2348866-B1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD (IL) | 2015-01-07 | — | — | EP | disclosed |
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | VASCULAR BIOGENICS LTD. (IL) | 2013-08-08 | — | — | US | disclosed |
| CN-102271517-A | oxidized lipid compounds and uses thereof | — | 2011-12-07 | — | — | CN | disclosed |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | VASCULAR BIOGENICS LTD. (IL) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203707-A1 | Oxidized Lipid Compounds and Uses Thereof | LPO, GPX4, ALOX15B | CNR1 2066/4885CNR2 1326/4885ALDH1A1 616/4885 |
| US-20110207703-A1 | OXIDIZED LIPID COMPOUNDS AND USES THEREOF | LPO, GPX4, ALOX15B | CNR1 2066/4885CNR2 1326/4885ALDH1A1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.